qualification honor

Beijing bokangjian Gene Technology Co., Ltd. is committed to become one of the backbone enterprises in China's biopharmaceutical industry. In order to achieve this goal, the company first consolidated its daily earnings by producing and selling chemicals with great market potential, and invested heavily in the research and development of exclusive DNA recombinant drugs. The third phase of clinical application of the company's new products recombinant insulin-4 and recombinant human tripeptide (rhPTH1-34) has ended. It is planned to pass the GMP certification and enter into formal production in 2019, with the output value reaching the goal of single product sales of more than 100 million.